Laboratory of Exercise Biochemistry, Department of Sports Sciences, University of Taipei
Taipei, Taiwan, 11153
NCT Number: NCT06626867
Metabolic syndrome includes hypertension(high blood pressure), hyperglycemia(high blood suger), dyslipidemia(abnormal blood lipid level) and obesity. The more items that meet metabolic syndrome, the higher the risk of cardiovascular disease and diabetes, and the higher the combined mortality. At present, research reports point out that the occurrence of metabolic syndrome is related to age, obesity, lifestyle and genetics.
The lack of sleep may reduce the diversity of intestinal flora, and conversely, if the diversity of intestinal flora can be increased, the quality of sleep may be improved. Dietary fiber can improve intestinal microflora and related indexes of metabolic syndrome.
Although recent studies have demonstrated that dietary fiber will affect obesity, mood and sleep, different kinds of dietary fiber will affect different strains and pro-duce different effects. The effect of resistant starch on metabolic syndrome, mood and sleep of obese people is not very clear. Therefore, the objective of this intervention trial was to evaluate the effects of the intake of resistant starch on sleep, mood, changes in body composition and biomarkers in metabolic syndrome.
Looking for future studies?
Notify Me30 year–65 year
All sexes
Interventional
Not applicable
Taipei, Taiwan, 11153
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each participant ingested either dietary fiber or placebo. The dietary fiber is indi-gestible dextrin (The WiseMan's Dining, KING CAR OTSUKA CO., Taipei, Taiwan). The dosage of contents in each package is 6 grams, 3 packs a day, with a total dose of 18 grams.
The placebo was a colored capsule with 5 grams of maltodextrin, which is taken once a day.
Time frame: From enrollment to the end of treatment at 8 weeks
Body fat percentage was estimated by dual-energy X-ray absorptiometry (DEXA; GE Lunar Prodigy 8743, Madison, WI, USA). The same experienced technician performed the analysis of the scan.
Time frame: From enrollment to the end of treatment at 8 weeks
Fasting blood samples were obtained at morning after the participants had 12 h of overnight fasting. To obtain plasma or serum, the blood samples with 5 ml collected into blood sampling tubes with or without ethylene diamine tetraacetic acid (EDTA), respectively, were centrifuged at 3000 rpm at 4 °C for 15 min and then stored at -80 °C until analysis. The plasma blood samples were assessed using fully automated analyz-er (AU5800, Beckman Coulter®, America). A set of standard samples will be collected and analysed on the same day, including fasting glucose(mmol/L).
Time frame: From enrollment to the end of treatment at 8 weeks
The Profile of Mood States, Revised (POMS-R) is an updated version of the original Profile of Mood States (POMS) questionnaire. It is a self-report tool used to assess a person's mood by measuring different dimensions of affective states, include:
This scoring system helps provide a snapshot of a person's emotional state across various mood domains.
Time frame: From enrollment to the end of treatment at 8 weeks
The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire used to assess sleep quality over a 1-month period. It includes 19 items grouped into seven components:
Each component is scored from 0 to 3, with a total score range of 0 to 21. A score above 5 indicates poor sleep quality.
Time frame: From enrollment to the end of treatment at 8 weeks
Fasting blood samples were obtained at morning after the participants had 12 h of overnight fasting. To obtain plasma or serum, the blood samples with 5 ml collected into blood sampling tubes with or without ethylene diamine tetraacetic acid (EDTA), respectively, were centrifuged at 3000 rpm at 4 °C for 15 min and then stored at -80 °C until analysis. The plasma blood samples were assessed using fully automated analyz-er (AU5800, Beckman Coulter®, America). A set of standard samples will be collected and analysed on the same day, including fasting glucose, high sensitivity C-reactive protein (HsCRP), fasting insulin, total cholesterol, low density lipoprotein (LDL-C), high density lipoprotein (HDL-C) and triglyceride (TG). Insulin was measured by us-ing electrochemiluminescence immunoassay (ECLIA) (Cobas e801, Roche Diagnostics, Mannheim, Germany); glycated hemoglobin (HbA1c) was measured by using an ion exchange resin composed of hydrophilic polymer of methacrylate ester copolymer (H
Time frame: From enrollment to the end of treatment at 8 weeks
Fasting blood samples were obtained at morning after the participants had 12 h of overnight fasting. To obtain plasma or serum, the blood samples with 5 ml collected into blood sampling tubes with or without ethylene diamine tetraacetic acid (EDTA), respectively, were centrifuged at 3000 rpm at 4 °C for 15 min and then stored at -80 °C until analysis. The plasma blood samples were assessed using fully automated analyz-er (AU5800, Beckman Coulter®, America). A set of standard samples will be collected and analysed on the same day, including high sensitivity C-reactive protein (HsCRP)(mg/L).
Time frame: From enrollment to the end of treatment at 8 weeks
Fasting blood samples were obtained at morning after the participants had 12 h of overnight fasting. To obtain plasma or serum, the blood samples with 5 ml collected into blood sampling tubes with or without ethylene diamine tetraacetic acid (EDTA), respectively, were centrifuged at 3000 rpm at 4 °C for 15 min and then stored at -80 °C until analysis. The plasma blood samples were assessed using fully automated analyz-er (AU5800, Beckman Coulter®, America). A set of standard samples will be collected and analysed on the same day, including total cholesterol(mmol/L).
Time frame: From enrollment to the end of treatment at 8 weeks
Fasting blood samples were obtained at morning after the participants had 12 h of overnight fasting. To obtain plasma or serum, the blood samples with 5 ml collected into blood sampling tubes with or without ethylene diamine tetraacetic acid (EDTA), respectively, were centrifuged at 3000 rpm at 4 °C for 15 min and then stored at -80 °C until analysis. The plasma blood samples were assessed using fully automated analyz-er (AU5800, Beckman Coulter®, America). A set of standard samples will be collected and analysed on the same day, including triglyceride (TG)(mmol/L).
Time frame: From enrollment to the end of treatment at 8 weeks
Blood pressure will be measured from the non-dominant arm with a digital blood pressure monitor (Omron HEM-7121, Japan) in sitting position after at least 15 min of rest, including diastolic blood pressure and systolic blood pressure.
Time frame: From enrollment to the end of treatment at 8 weeks
Body height and weight will be measured on a stadiometer (Takei Scientific In-struments, Tokyo, Japan) and digital scale (TANITA WB-110MA, Tokyo, Japan) to the nearest 0.1 cm and 0.1 kg without shoes and wearing light clothes. Waist circumference was measured at the midpoint between the iliac crest and the lowest rib margin, and hip circumference was assessed at the widest point around the buttocks. Based on the anthropometric metric measures, body mass index (BMI; kg/m2) and waist to hip ratio (WHR; waist/hip) were calculated.
Chien-Wen Hou
Other
Effect of Dietary Fiber on Metabolic Syndrome, Gastrointestinal Function, Mood and Sleep Quality
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06694012
Arterial Occlusive Diseases, Arteriosclerosis
Sakai, Osaka, Japan
View Trial DetailsNCT07119658
Body Weight, Cardiovascular Diseases
Indianapolis, Indiana, United States
View Trial DetailsNCT05685017
Abdominal Obesity, Body Weight
Surabaya, East Java, Indonesia
View Trial DetailsNCT01428791
Behavior, Behavioral Symptoms
Chicago, Illinois, United States
View Trial Details